Patents Represented by Attorney, Agent or Law Firm Steve T. Zelson
  • Patent number: 7595329
    Abstract: This invention relates to compounds of the formula (I): wherein R1, R2, R3, A and m are each as described herein or a pharmaceutically acceptable salt or solvate thereof, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 receptor activity such as, but not limited to, gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders such as cardiac failure and heart arrhythmia, diabetes and apnea syndrome.
    Type: Grant
    Filed: June 14, 2005
    Date of Patent: September 29, 2009
    Assignee: Pfizer Inc
    Inventors: Koji Ando, Satoru Iguchi, Noriaki Murase, Yoshinori Murata, Toyoharu Numata, Hiroki Sone, Chikara Uchida, Tatsuo Ueki
  • Patent number: 7550428
    Abstract: A complex of an echinocandin compound with a carbohydrate is described having improved thermal stability and water solubility. A process for making the echinocandin/carbohydrate complex is also described as well as the use of the complex in pharmaceutical formulations and treatments of fungal infections.
    Type: Grant
    Filed: August 30, 2005
    Date of Patent: June 23, 2009
    Assignee: Eli Lilly and Company
    Inventors: Larry A. Larew, Nathaniel Milton, James Lawrence Sabatowski, Kenneth Philip Moder
  • Patent number: 7524860
    Abstract: The present invention is directed to a new class of triazolopyridine derivatives, to their use as antimicrobials, and to pharmaceuticals containing these compounds.
    Type: Grant
    Filed: September 23, 2005
    Date of Patent: April 28, 2009
    Assignee: Pfizer Inc.
    Inventors: David Charles Donnell Butler, Huifen Chen, Vishnumurthy Ramachandra Hegde, Chris Limberakis, Ravindra Madhukar Rasne, Richard John Sciotti, Jeremy Tyson Starr
  • Patent number: 7517909
    Abstract: This invention relates to certain ?-amino acids that bind to the alpha-2-delta (?2?) subunit of a calcium channel. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other disorders.
    Type: Grant
    Filed: March 14, 2006
    Date of Patent: April 14, 2009
    Assignee: Pfizer Inc
    Inventors: Andrew John Thorpe, David Juergen Wustrow
  • Patent number: 7491835
    Abstract: This invention relates to prodrugs of certain amino acids that bind to the alpha-2-delta (?2?) subunit of a calcium channel. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other disorders.
    Type: Grant
    Filed: September 21, 2004
    Date of Patent: February 17, 2009
    Assignee: Pfizer Inc
    Inventors: Sean D. Donevan, Augustine Tobi Osuma, Andrew J. Thorpe, David Juergen Wustrow
  • Patent number: 7473787
    Abstract: The present invention relates to a series of substituted bicyclic[3.1.0]amines of the Formula I: wherein A, B, D, Q, V, W, X, Y, Z, R2, R3, R4, R5, R14, R15, R30. o, p, s,t and q are as defined in the specification, their pharmaceutically acceptable salts, pharmaceutical compositions thereof, and their use for the enhancement of cognition and the treatment of the positive and negative symptoms of schizophrenia and other psychoses in mammals, including humans.
    Type: Grant
    Filed: October 14, 2004
    Date of Patent: January 6, 2009
    Assignee: Pfizer Inc
    Inventors: Stanton McHardy, John A. Lowe
  • Patent number: 7473790
    Abstract: The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1 and R2, are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula 1, and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.
    Type: Grant
    Filed: May 8, 2006
    Date of Patent: January 6, 2009
    Assignee: Pfizer Inc.
    Inventors: Allen Borchardt, Javier Gonzalez, Hui Li, Maria Angelica Linton, John Howard Tatlock
  • Patent number: 7468375
    Abstract: The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus (“HIV”) integrase enzyme.
    Type: Grant
    Filed: April 25, 2005
    Date of Patent: December 23, 2008
    Assignee: Pfizer Inc.
    Inventors: Klaus Ruprecht Dress, Qiyue Hu, Ted William Johnson, Michael Bruno Plewe, Steven Paul Tanis, Hai Wang, Anle Yang, Chunfeng Yin, Junhu Zhang
  • Patent number: 7462600
    Abstract: Macrolide compounds per se, as shown below and defined herein, and their use, e.g., as antibacterial and antiprotozoal agents in animals, including humans: Also disclosed are methods of preparing the compounds, intermediates, and pharmaceutical compositions thereof, and methods of treating or preventing disease by administering the compounds to subjects in need. This abstract is only an excerpt and is not limiting of the invention.
    Type: Grant
    Filed: December 21, 2005
    Date of Patent: December 9, 2008
    Assignee: Pfizer Inc
    Inventors: Louis S. Chupak, Mark E. Flanagan, Takushi Kaneko, Thomas V. Magee, Mark C. Noe, Usa Reilly
  • Patent number: 7456177
    Abstract: The present invention provides a compound having the structure of formula I: wherein R1 is hydrogen, (C1–C6) alkyl, unconjugated (C3–C6) alkenyl, benzyl, YC(?O)(C1–C6) alkyl or —CH2CH2—O—(C1–C4) alkyl; X is CH2 or CH2CH2; Y is (C2–C6) alkylene; Z is (CH2)m, CF2, or C(?O), where m is 0, 1 or 2; R2 and R3 are selected independently from hydrogen, halogen, —(C1–C6) alkyl optionally substituted with from 1 to 7 halogen atoms, and —O(C1–C6) alkyl optionally substituted with from 1 to 7 halogen atoms, or R2 and R3 each together with the atom to which it is connected independently form C(?O), S?O, S(?O)2, or N?O; and is a 5- to 7-membered monocyclic heteroaryl group selected from pyridinyl, pyridone, pyridazinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, cinnolinyl, triazinyl, oxadiazolyl, thiadiazolyl and furazanyl groups.
    Type: Grant
    Filed: July 12, 2004
    Date of Patent: November 25, 2008
    Assignee: Pfizer Inc.
    Inventors: Martin P. Allen, Jotham W. Coe, Spiros Liras, Christopher J. O'Donnell, Brian T. O'Neill
  • Patent number: 7456164
    Abstract: The invention relates to 3- or 4-monosubstituted phenol and thiophenol derivatives of formula (I) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. Said 3- or 4-monosubstituted phenol and thiophenol derivatives are H3 ligands and are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.
    Type: Grant
    Filed: May 9, 2005
    Date of Patent: November 25, 2008
    Assignee: Pfizer, Inc
    Inventors: Patrick Bernardelli, Andrew Michael Cronin, Alexis Denis, Stephen Martin Denton, Henry Jacobelli, Mark Ian Kemp, Edwige Lorthiois, Fiona Rousseau, Delphine Serradeil-Civit, Fabrice Vergne
  • Patent number: 7439236
    Abstract: The present invention relates to compounds of formula I The substituent designations are as disclosed. At least one of B, Q, D and E is nitrogen. The present invention also provides a method of treating disorders of the Central Nervous System such as schizophrenia and cognitive dysfunction.
    Type: Grant
    Filed: November 15, 2006
    Date of Patent: October 21, 2008
    Assignee: Pfizer Inc
    Inventors: Brian Thomas O'Neill, Jotham Wadsworth Coe, Christopher J. O'Donnell
  • Patent number: 7435728
    Abstract: This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivative thereofs, wherein R1 to R4 are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).
    Type: Grant
    Filed: June 20, 2005
    Date of Patent: October 14, 2008
    Assignee: Pfizer Inc
    Inventors: Lyn Howard Jones, Charles Eric Mowbray, David Anthony Price, Matthew Duncan Selby, Paul Anthony Stupple
  • Patent number: 7435751
    Abstract: The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof wherein R1 is C1-4alkyl, optionally substituted with a fluoro atom, or R1 is a cyclopropyl or cyclopropylmethyl; and R2 is methyl or ethyl. These compounds are useful as antibacterial agents.
    Type: Grant
    Filed: March 30, 2006
    Date of Patent: October 14, 2008
    Inventors: Vara Prasad Venkata Nagendra Josyula, Mikhail Gordeev, Gary Luehr
  • Patent number: 7429665
    Abstract: The invention pertains to heteroaromatic compounds that serve as effective phosphodiesterase (PDE) inhibitors. In particular, the invention relates to said compounds which are selective inhibitors of PDE10. The invention also relates to intermediates for preparation of said compounds; pharmaceutical compositions comprising said compounds; and the use of said compounds in a method for treating certain central nervous system (CNS) or other disorders.
    Type: Grant
    Filed: January 5, 2006
    Date of Patent: September 30, 2008
    Assignee: Pfizer Inc
    Inventors: Patrick R. Verhoest, Christopher J. Helal, Dennis J. Hoover, John M. Humphrey
  • Patent number: 7384773
    Abstract: The x-ray crystal structure of human BACE or BACE-like proteins is useful for solving the structure of other molecules or molecular complexes, and identifying and/or designing potential modifiers of human BACE activity.
    Type: Grant
    Filed: May 10, 2002
    Date of Patent: June 10, 2008
    Assignee: Pfizer Inc
    Inventors: Timothy E. Benson, Jim D. Durbin, Thomas L. Emmons, Alfredo G. Tomasselli
  • Patent number: 7381741
    Abstract: 3-amino-2-phenylpyrrolidine compounds useful as NK-1 antagonists, with pharmaceutical compositions and methods of treatment comprising same, are disclosed.
    Type: Grant
    Filed: May 25, 2005
    Date of Patent: June 3, 2008
    Assignee: Pfizer Inc
    Inventors: John Michael Humphrey, Thomas Allen Chappie
  • Patent number: 7368571
    Abstract: Bicycling hydroxamate compounds represented by the Formula I: are described. The bicyclic hydroxamate compounds and compositions containing those compounds may be used to inhibit or modulate an enzyme activity of HIV Integrase and to treat HIV mediated diseases and conditions.
    Type: Grant
    Filed: September 6, 2006
    Date of Patent: May 6, 2008
    Assignee: Pfizer Inc
    Inventors: Qiyue Hu, Atsuo Kuki, Dawn Marie Nowlin, Michael Bruno Plewe, Hai Wang, Junhu Zhang
  • Patent number: 7361743
    Abstract: Novel lincomycin derivatives are disclosed. These lincomycin derivatives exhibit antibacterial activity. The compounds of the subject invention may exhibit potent activities against bacteria, including Gram positive organisms, and may be useful antimicrobial agents. Methods of synthesis and of use of the compounds are also disclosed.
    Type: Grant
    Filed: August 31, 2005
    Date of Patent: April 22, 2008
    Assignee: Pfizer Inc
    Inventors: Jason G. Lewis, Sampath K Anandan, Hardwin O'Dowd, Mikhail F Gordeev, Liansheng Li
  • Patent number: 7309790
    Abstract: The present invention provides compounds of formula (I) wherein R1 and R2 are as defined hereinabove. The compounds of the present invention are modulators, especially antagonists, of the activity of chemokine CCR5 receptors. Modulators of the CCR5 receptor may be useful in the treatment of various inflammatory diseases and conditions, and in the treatment of infection by HIV and genetically related retroviruses.
    Type: Grant
    Filed: September 28, 2004
    Date of Patent: December 18, 2007
    Assignee: Pfizer Inc
    Inventor: Paul Anthony Stupple